Insider · CIK 0002050176
Ping Zhang
Files at GYRE (GYRE THERAPEUTICS, INC.). First filing -, latest -.
In brief
Ping Zhang files SEC Form 4 as director at GYRE (GYRE THERAPEUTICS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ping Zhang has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 30, 2026 |
| May 14, 2026 | GYRE GYRE THERAPEUTICS, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -250,000 | $0.00 | $0 | 0 | May 20, 2026 |
| Jan 7, 2026 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 9, 2026 |
| Aug 5, 2025 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Aug 7, 2025 |
| May 27, 2025 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | May 28, 2025 |
| Jan 5, 2025 | GYRE GYRE THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +52,000 | $0.00 | $0 | 52,000 | Jan 7, 2025 |
Questions about Ping Zhang
Answered from the filings on this page, as of the latest one.
Is Ping Zhang buying or selling?
Ping Zhang has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ping Zhang's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ping Zhang has 0.
Where does Ping Zhang file Form 4?
Ping Zhang has filed Form 4 at GYRE (GYRE THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.